- Home
- LIN vs AZN Comparison
LIN vs AZN Comparison
Compare LIN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIN
- AZN
- Stock Information
- Founded
- LIN 1879
- AZN 1992
- Country
- LIN United Kingdom
- AZN United Kingdom
- Employees
- LIN N/A
- AZN N/A
- Industry
- LIN Major Chemicals
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- LIN Industrials
- AZN Health Care
- Exchange
- LIN Nasdaq
- AZN Nasdaq
- Market Cap
- LIN 217.0B
- AZN 228.9B
- IPO Year
- LIN N/A
- AZN 1993
- Fundamental
- Price
- LIN $472.89
- AZN $72.66
- Analyst Decision
- LIN Buy
- AZN Strong Buy
- Analyst Count
- LIN 13
- AZN 3
- Target Price
- LIN $513.73
- AZN $95.00
- AVG Volume (30 Days)
- LIN 1.6M
- AZN 4.1M
- Earning Date
- LIN 08-01-2025
- AZN 07-29-2025
- Dividend Yield
- LIN 1.27%
- AZN 2.09%
- EPS Growth
- LIN 6.99
- AZN 22.71
- EPS
- LIN 13.78
- AZN 4.97
- Revenue
- LIN $33,017,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- LIN $2.72
- AZN $9.56
- Revenue Next Year
- LIN $5.57
- AZN $6.09
- P/E Ratio
- LIN $34.33
- AZN $14.62
- Revenue Growth
- LIN 0.78
- AZN 15.48
- 52 Week Low
- LIN $408.65
- AZN $61.24
- 52 Week High
- LIN $487.49
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- LIN 57.46
- AZN 57.29
- Support Level
- LIN $462.44
- AZN $68.61
- Resistance Level
- LIN $476.38
- AZN $74.38
- Average True Range (ATR)
- LIN 6.37
- AZN 1.03
- MACD
- LIN 0.37
- AZN 0.34
- Stochastic Oscillator
- LIN 82.55
- AZN 70.19
About LIN Linde plc
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $33 billion in revenue in 2024.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.